NEW YORK, Jan. 25, 2007 (PRIME NEWSWIRE) -- A National Stem Cell senior leadership team traveled to China to cultivate scientific and business relationships with the intent of launching National Stem Cell's operations in the region.
National Stem Cell is planning to create structures for phased stem cell therapeutic development in China. At the same time the company is in end-stage negotiations with a prestigious academic institution to facilitate the expansion of its research capabilities.
CEO Michael Cohen and Dr. Ian McNiece, a Scientific Advisory Board member, both concurred that the areas of interest for the company in China include: therapeutic development, umbilical cord blood banking, and partnering with leading stem cell scientists in order to enhance its laboratory research.
Mr. Cohen states, "Particularly in the area of cord blood banking we were fascinated to be told that in a country of 1.3 billion people there are only 10 licensed cord blood banks, all of them private. Since our upcoming cord blood banking model will be a combination of public and private banking, we see an incredible opportunity to serve the people of China while expanding our business operations."
National Stem Cell Holding, Inc. (Pink Sheets:NHGI) is a biotechnology company headquartered in New York City dedicated to the advancement of regenerative medicine. Through its sponsored research agreement with the Johns Hopkins University School of Medicine's Institute for Cell Engineering, National Stem Cell is focused on the development of potential stem cell therapies for the treatment of diabetes and cardiac injury. The company is planning to establish a genetically diverse umbilical cord blood bank to meet the growing need for transplant grade umbilical cord blood stem cells. National Stem Cell Holding, Inc. is the parent company of National Stem Cell, Inc., incorporated in 2005, which operates the Sperm Bank of New York as a wholly owned subsidiary. For more information, please visit www.nationalstemcell.com.
Forward-Looking Statements:
As provided by the "Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995," National Stem Cell Holding, Inc. cautions readers that this Press Release includes certain information which constitutes forward-looking statements. Such forward-looking statements address the company's intentions, hopes, expectations, strategies, and financial or business outlook for the future. The statements are based on management's current beliefs and expectations and thus, apply only as of the date of this Press Release. There are a number of risks and uncertainties that could cause actual results or events to differ materially from management's current beliefs and expectations. Risk factors include but are not limited to National Stem Cell Holding, Inc.'s ability to successfully complete its 2006 financial audit, as well as general economic, competitive, governmental and technological factors. National Stem Cell Holding, Inc. does not undertake any obligation or responsibility to update forward-looking statements.